| Sep 20 |
Zevra Therapeutics gains FDA approval of arimoclomol for rare neurological disease
|
| Sep 6 |
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
|
| Aug 29 |
Zevra Therapeutics to Participate at Upcoming Investor Conferences
|
| Aug 19 |
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
|
| Aug 15 |
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
|
| Aug 14 |
Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 13 |
Zevra Therapeutics GAAP EPS of -$0.48 misses by $0.04, revenue of $445M beats by $440.64M
|
| Aug 13 |
Zevra Therapeutics: Q2 Earnings Snapshot
|
| Aug 13 |
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
